Recent Company News

• 12:07 PM ET Oct 25, 2025
  

  Swedish Orphan Biovitrum announces new data from completed and ongoing studies of Nanoecapsulated Sirolimus plus Pegadricase (NASP, formerly SEL-212), Vonjo (pacritinib), and Gamifant (emapalumab-lzsg) (SEK 318.60, 0.00)

• 07:11 AM ET Oct 24, 2025
  

  Swedish Orphan Biovitrum showcases new data across rare inflammatory conditions at ACR 2025 (SEK 314.80, +0.40)

• 11:11 AM ET Oct 21, 2025
  

  FDA approves sBLA for Beyfortus, adds clinical data to label (12470.0000p, -94)

• 08:56 AM ET Oct 20, 2025
  

  Transcript Intelligence: Swedish Orphan Biovitrum Q3 Earnings Guidance (SEK307.40, -4.20)

• 08:56 AM ET Oct 20, 2025
  

  Transcript Intelligence: Swedish Orphan Biovitrum Q3 Earnings Themes (SEK307.40, -4.20)

• 08:55 AM ET Oct 20, 2025
  

  Transcript Intelligence: Swedish Orphan Biovitrum Q3 Earnings Q&A (SEK307.40, -4.20)

• 04:06 AM ET Oct 20, 2025
  

  Swedish Orphan Biovitrum reports final Q3 earnings in line with prelim. release; EPS SEK6.05 ex-items vs FactSet SEK4.65 [7 est, SEK4.32-5.06] (pre-EU open) (SEK 310.80, -0.80)

• 02:14 AM ET Oct 20, 2025
  

  StreetAccount Metrics Recap - Swedish Orphan Biovitrum Q3 Earnings (SEK 311.60, 0.00)

• 03:38 PM ET Oct 19, 2025
  

  Swedish Orphan Biovitrum reports preliminary Q3 revenue SEK7.78B vs FactSet SEK7.73B [9 est, SEK7.34-8.27B]; to report Q3 on 20-Oct (SEK 311.60, 0.00)

• 06:26 AM ET Oct 02, 2025
  

  StreetAccount Summary - European unusual volume traders